Digoksin İntoksikasyonu

Withering W. An Account of the Foxglove, and Some of its Medical Uses - William Withering - Google Kitaplar. Accessed January 21, 2024.
Hollman, A. "Drugs for atrial fibrillation. Digoxin comes from Digitalis lanata." BMJ: British Medical Journal 312.7035 (1996): 912.
Kotecha D, Bunting K V, Gill SK, et al. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA. 2020;324(24):2497-2508. doi:10.1001/JAMA.2020.23138
Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. doi:10.1136/bmj.h4451
Gheorghiade M, Pitt B. Digitalis Investigation Group (DIG) trial: A stimulus for further research. Am Heart J. 1997;134(1):3-12. doi:10.1016/S0002-8703(97)70100-5
Hauptman PJ, Kelly RA. Digitalis. Circulation. 1999;99(9):1265-1270. doi:10.1161/01.CIR.99.9.1265
Morris SA, Hatcher HF, Reddy DK. Digoxin Therapy for Heart Failure: An Update. Am Fam Physician. 2006;74(4):613-618. Accessed January 23, 2024.
Ordog GJ, Benaron S, Bhasin V, Wasserberger J, Balasubramanium S. Serum digoxin levels and mortality in 5,100 patients. Ann Emerg Med. 1987;16(1):32-39. doi:10.1016/S0196-0644(87)80281-0
Cummings ED, Swoboda HD. Digoxin Toxicity. StatPearls Publishing. 2023;06:6. Accessed January 23, 2024. https://www.ncbi.nlm.nih.gov/books/NBK470568/
Lapostolle F, Borron SW, Verdier C, et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med. 2008;34(8):1448-1453. doi:10.1007/S00134-008-1092-X/METRICS
Fozzard HA, Sheets MF. Cellular mechanism of action of cardiac glycosides. J Am Coll Cardiol. 1985;5(5):10A-15A. doi:10.1016/S0735-1097(85)80458-7
Eichhorn EJ, Gheorghiade M. Digoxin. Prog Cardiovasc Dis. 2002;44(4):251-266. doi:10.1053/PCAD.2002.31591
Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation. 1989;80(1):65-77. doi:10.1161/01.CIR.80.1.65
Hausner H, Julie •, Karsbøl D, et al. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clin Pharmacokinet. 2017;56:1391-1401. doi:10.1007/s40262-017-0532-6
Zyoud SH, Waring WS, Al-Jabi SW, et al. Bibliometric profile of global scientific research on digoxin toxicity (1849–2015). Drug Chem Toxicol. 2020;43(6):553-559. doi:10.1080/01480545.2018.1518453
Thiemann DR. Digitalis and hemodialysis is a bad combination. Journal of the American Society of Nephrology. 2010;21(9):1418-1420. doi:10.1681/ASN.2010070775
Oishi A, Miyamoto K, Kashii S, et al. Photopsia as a manifestation of digitalis toxicity. Can J Ophthalmol. 2006;41:603-607.
Rosen MR, Wit AL, Hoffman BF. Electrophysiology and pharmacology of cardiac arrhythmias. IV. Cardiac antiarrhythmic and toxic effects of digitalis. Am Heart J. 1975;89(3):391-399. doi:10.1016/0002-8703(75)90090-3
BMJ Best Practice. Digoxin Toxicity Straight to the Point of Care.; 2023. Accessed January 5, 2024. https://bestpractice.bmj.com/topics/en-gb/3000257
Andrews P, Anseeuw K, Kotecha D,et al. Diagnosis and practical management of digoxin toxicity: A narrative review and consensus. European Journal of Emergency Medicine. 2023;30(6):395-401. doi:10.1097/MEJ.0000000000001065
Chan BSH, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014;52(8):824-836. doi:10.3109/15563650.2014.943907
Pincus M. Management of digoxin toxicity. Aust Prescr. 2016;39(1):18. doi:10.18773/AUSTPRESCR.2016.006
Antman EM, Wenger TL, Butler VP, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81(6):1744-1752. doi:10.1161/01.CIR.81.6.1744
Gheorghiade M, Van Veldhuisen DJ, Colucci WS. Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. Circulation. 2006;113(21):2556-2564. doi:10.1161/CIRCULATIONAHA.105.560110
Ujhelyi MR, Robert S. Pharmacokinetic Aspects of Digoxin-Specific Fab Therapy in the Management of Digitalis Toxicity. Clin Pharmacokinet. 1995;28(6):483-493. doi:10.2165/00003088-199528060-00006/METRICS